Carboplatin–Angelica gigas Nakai combination synergistically enhances apoptosis by suppressed Akt, Erk, and Stat3 expression in H460 human lung cancer cells. (October 2018)

• Record Type: Journal Article
• Authors: Ku, Jin Mo; Hong, Se Hyang; Kim, Hyo In; Jung, Jun Seok; Jung, Myung Ju; Kim, Ji Hye; Seo, Hye Sook; Shin, Yong Cheol; Ko, Seong-Gyu
• Is Part Of: European journal of inflammation. Volume 16(2018)
• Publication Date: 2018-10
• Subjects: AGN -- Akt -- carboplatin -- H460 cells -- lung cancer -- Stat3; Inflammation -- Periodicals; Anti-Inflammatory Agents -- therapeutic use -- Periodicals; Immunotherapy -- Periodicals; Inflammation -- Periodicals; Anti-inflammatory agents -- Periodicals; Immunotherapy -- Periodicals; Anti-inflammatory agents; Immunotherapy; Inflammation; Periodicals; 616.0473
• DOI: 10.1177/2058739218805343
• Languages: English
• ISSNs: 1721-727X

Abstract

The lower potency of low dose of carboplatin often requires combination with other drugs to improve its efficacy. Newer and more potent carboplatin-based combination therapies are investigated for treatment. We investigated whether paclitaxel, carboplatin, and Angelica gigas Nakai (AGN) affect viability of H460 cells by MTT assay. Western blot analysis was used to measure the expression of various modulators, such as p-Stat3, p-Akt, and p-Erk. Paclitaxel, carboplatin, and AGN affected the viability of H460 cells. Paclitaxel, carboplatin, and AGN suppressed p-Akt, p-Erk, and p-Stat3 expression. AGN combined with carboplatin significantly decreased c-Jun, HIF-1α, and VEGF levels. AGN combined with carboplatin significantly increased p21 and p27 levels and suppressed cyclin D1 and cyclin E levels. AGN combined with carboplatin-induced apoptosis by increasing Bax and cleavage of caspase and Parp level and by suppressing Bcl-2 level. Our results clearly demonstrate that AGN combined with carboplatin could be a useful compound for treating lung cancer.